Consequently, in 2019, the use of E2 in treating ERβ-positive TNBC patients was approved for clinical trials, and the phase II trial “Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer” has been launched (ClinicalTrials.gov Identifier: NCT03941730). The gene discussed is ESR2; the disease is triple-negative breast carcinoma.